Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:08:35 Source:styleViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:David Cronenberg's new grief
Next:Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
You may also like
- Queen Camilla reveals she's seen the first season of Bridgerton
- Hurricanes rely on veteran composure in the big rally for a 2
- How major US stock indexes fared Monday, 4/22/2024
- Analysis: Golf has two dominant forces in Scheffler and Korda. It didn't happen overnight
- Dame Judi Dench's tears as she receives Sycamore Gap tree seedling at Chelsea Flower Show
- Both bodies found five days after kayaks capsized going over a dangerous dam in Indianapolis
- Child care crisis: High daycare cost hurts moms without college degree
- Mistrial declared in case of Arizona rancher accused of murdering Mexican migrant on his land
- Verona confirms Serie A status for another year after beating Salernitana